Infectious Diseases Society of America 2022 Guidance on the Treatment of ExtendedSpectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTRP. aeruginosa)

Authors Pranita D. Tamma,1 Samuel L. Aitken,2 Robert A. Bonomo,3 Amy J. Mathers,4 David van Duin,5 & Cornelius J. Clancy6

Affiliations 1Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA 2Department of Pharmacy, University of Michigan Health, Ann Arbor, Michigan, USA 3Medical Service and Center for Antimicrobial Resistance and Epidemiology, Louis Stokes Cleveland Veterans Affairs Medical Center, University Hospitals Cleveland Medical Center and Departments of Medicine, Pharmacology, Molecular Biology, and Microbiology, Case Western Reserve University, Cleveland, Ohio, USA 4Departments of Medicine and Pathology, University of Virginia, Charlottesville, Virginia, USA 5Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA 6Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Corresponding Author: Pranita D. Tamma, MD, MHS, Johns Hopkins University School of Medicine, Department of Pediatrics, Baltimore, Maryland, USA; ptamma1@jhmi.edu

Alternate Corresponding Author: Cornelius J. Clancy, University of Pittsburgh, Department of Medicine, Pittsburgh, Pennsylvania, USA; cjc76@pitt.edu

Key words: Antimicrobial resistance; ceftolozane-tazobactam; ceftazidime-avibactam; cefiderocol; imipenem-cilastatin-relebactam; meropenem-vaborbactam

Provided by : Dr Rana Maghrabi

Read more..